As of Oct 27
| -5.57 / -1.88%|
The 21 analysts offering 12-month price forecasts for Biogen have a median target of 356.00, with a high estimate of 386.00 and a low estimate of 284.00. The median estimate represents a +22.38% increase from the last price of 290.89.
The current consensus among 24 polled investment analysts is to Buy stock in Biogen. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.